|
|
|
|
|
|
|
|
open access
Abstract
Cisplatin
and other platinum derivatives are the most widely used
chemotherapeutic agents to treat solid tumors including ovarian, head
and neck, and testicular germ cell tumors. A known complication of
cisplatin administration is acute kidney injury (AKI). The nephrotoxic
effect of cisplatin is cumulative and dose-dependent and often
necessitates dose reduction or withdrawal. Recurrent episodes of AKI may
result in chronic kidney disease. The pathophysiology of
cisplatin-induced AKI involves proximal tubular injury, oxidative
stress, inflammation, and vascular injury in the kidney. There is
predominantly acute tubular necrosis and also apoptosis in the proximal
tubules. There is activation of multiple proinflammatory cytokines and
infiltration of inflammatory cells in the kidney. Inhibition of the
proinflammatory cytokines TNF-α or IL-33 or depletion of CD4+ T
cells or mast cells protects against cisplatin-induced AKI. Cisplatin
also causes endothelial cell injury. An understanding of the
pathogenesis of cisplatin-induced AKI is important for the development
of adjunctive therapies to prevent AKI, to lessen the need for dose
decrease or drug withdrawal, and to lessen patient morbidity and
mortality.
1. Introduction
Acute
kidney injury (AKI) is defined as a clinical syndrome characterized by a
rapid decrease in renal (kidney) function together with the accumulation of
waste products such as urea [1].
The incidence of non-dialysis-requiring AKI is about 5000 cases per
million people per year and incidence of dialysis requiring AKI is 295
cases per million people per year [2]. AKI complicates 1–7% of all hospital admissions and 1–25% of intensive care unit admissions [3, 4].
Furthermore, AKI is known as an independent risk factor for mortality.
AKI increases the risk of death by 10- to 15-fold and results in a
mortality rate of 50% [5, 6]......
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.